How should the Federal Government prioritise medical research?

Published at Sep 7, 2016, in Features

Eighty-seven per cent of Australians support the Federal Government’s investment in the Medical Research Future Fund (MRFF).

That is the verdict of a Roy Morgan Research poll of 1,040 people conducted on behalf of Research Australia, which also shows 78 per cent of Australians believe the MRFF will lead to better health outcomes.

The Medical Research Future Fund will reach capacity in the next decade and deliver about $1 billion a year for new therapies, treatments, drugs and devices with direct benefits to Australians.

“It is clear there is significant support for the Medical Research Future Fund and Australians want to see it become a reality,” said CEO of Research Australia, Nadia Levin.

“The MRFF will make an enormous difference to the health of Australians and the health of our economy, and people realise that and the contribution of medical research.

“The community recognises medical research is paramount to improving health outcomes and want to see medical breakthroughs brought from the laboratory into hospitals and medical clinics.

“They see stories about potential medical breakthroughs and new hope on their TVs – and they want to then see that reflected in their hospitals and doctor’s surgeries as soon as possible.

“The MRFF is a key to bridging this gap, providing new therapies, treatments, drugs and devices that will directly benefit Australians.”

The question is: how do you prioritise which treatments are deserving of funding and how much should they receive?

Health Minister Susan Ley announced the MRFF back in April this year. It is led by Professor Ian Frazer, one of Australia’s most innovative and successful researchers who developed the highly successful human papillomavirus (HPV) vaccine that protects against cervical cancer.

It would seem that funding is in the hands of the right man.

However as The Conversation editorialised earlier this year: “Prioritising a health condition is tempting for governments. No-one would argue against the strongest possible worldwide research effort on any area of ill health, whether it’s to defeat, say, dementia, breast cancer or diabetes.

“But it is a poor way to get the most benefit for Australia. Even devoting all of the Australian MRFF to a single disease would represent only a tiny increase in the worldwide research effort (perhaps by 1-2%). This is unlikely to make much difference, no matter how large the burden of the disease on individuals and societies.”

Even back in August 2015, there were concerns about how the funds would be allocated.

Michael Edwards of the ABC’s AM program reported, “Doctors are welcoming the establishment of Australia’s medical research fund but concerns persist about how the grants will be allocated.”

However, Edwards went on to report that according to the government the multi-billion-dollar-program will strengthen Australia’s standing as a global leader in research.

Which is a benefit in itself.

Another positive of the MRFF, despite Labor concerns the grant is open to political interference, is the amount of money being allocated per year.

At one billion dollars every year, medical research should receive a significant boost.

It is hoped that research being done in the small cap space will benefit as much as the large research companies and big pharma and that companies such as Dimerix, Actinogen Medical, Noxopharm, Cellmid, MGC Pharma, MMJ Phytotech and Race Oncology, which are all doing important work in the spheres of cancer, diabetes, epilepsy and Alzeimer’s Disease, could potentially benefit.

The MRFF will be working closely with the government on policy settings and projects over the coming weeks and months.

Highlights of the poll include:

  • 87% of Australians support the MRFF and 78% believe research funded by the MRFF will lead to better health.
  • 88% of Australians believe healthcare is the area where scientific research is most important.
  • Health and medical research is ‘very’ and ‘extremely’ important to making discoveries about human health and disease (85%), and turning discoveries into new drugs and treatments (84%).
  • 88% of people rated ‘basing healthcare on the best and most recent research’ as key to improving the health system, compared to reducing waiting times in emergency departments (80%) and more doctors in regional areas (78%).

For a copy of the full poll:

Where to invest $1,000 right now

When the experts at Next Investors have a stock pick, it may pay to listen.

The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.

They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.

Click the link below to see what they are currently investing in.


S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!